TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Other Events
Item 8.01
|
Other Information. |
We are providing in Exhibit 99.1, which is incorporated herein by
reference, certain disclosures required by Part III of our Annual
Report on Form 10-K for the year ended December 31, 2016.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Form 10-K, Part III Disclosures |
About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Recent Trading Information
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) closed its last trading session up +0.10 at 4.20 with 58,004 shares trading hands.
